ERBB2 and breast cancer: The CLEOPATRA trial was presented at the 2011 San Antonio Breast Cancer Symposium and published that same day in The New England Journal of Medicine, with striking results of prolonged PFS in the metastatic setting of HER2-positive disease (National Institutes of Health [NIH], 2015).